What the agency asks
The agency asks to revise this rider.
Struck text is struck through in the request, which is how an agency marks words to
remove. Underlined text is underlined there, which is how it marks words to add. The marks are shown as
they are on the page; an agency sometimes underlines a remark of its own.
Vendor Drug Rebates and Report. All references in this rider to rebate revenue refer to vendor drug rebates as well as supplemental rebates earned via the preferred drug lists (methods of finance include Vendor Drug Rebates-Medicaid No. 706, Vendor Drug Rebates-CHIP No. 8070, Vendor Drug Rebates-Supplemental Rebates No. 8081, and Vendor Drug Rebates-Public Health No. 8046). (a) Rebates as a First Source of Funding. As rebates are generated, expenditures to support prescription drugs in Medicaid, Children's Health Insurance Program (CHIP), Healthy Texas Women (HTW), Children with Special Health Care Needs (CSHCN), and Kidney Health Care (KHC) shall be made from rebate revenues. In the event rebate revenues are not available for expenditure, appropriations from the General Revenue Fund may be used to support prescription drug expenditures until rebate revenues are available. (b) Appropriation of Medicaid and CHIP Rebates. In addition to rebate revenues appropriated above in Strategies A.1.1, Medicaid Client Services, and C.1.1, CHIP, the Health and Human Services Commission (HHSC) is appropriated Medicaid and CHIP vendor drug rebates generated in excess of those amounts, subject to the following requirements: (1) Vendor drug rebates shall be expended prior to utilization of any appropriations from the General Revenue Fund available for the purpose of Medicaid and CHIP prescription drugs. (2) In the event appropriations from the General Revenue Fund has been expended prior to the receipt of vendor drug rebates, HHSC shall reimburse General Revenue. HHSC shall reimburse the General Revenue Fund with vendor drug rebates on a monthly basis. (3) Program Benefit Agreement revenues collected in lieu of state supplemental rebates will be expended prior to utilization of any appropriations from the General Revenue Fund available for the purpose of the Medicaid program specified in the Agreement. (c) Appropriation of HTW, CSHCN, and KHC Rebates. In addition to rebate revenue appropriated above in Strategies D.1.1, Women's Health Programs; D.1.7, Children with Special Needs; and D.1.9, Kidney Health Care, HHSC is appropriated vendor drug rebates generated in excess of those amounts, subject to the following requirements: (1) Vendor drug rebates shall be expended prior to utilization of any appropriations from the General Revenue Fund appropriated for the purpose of operating the HTW, CSHCN, and KHC programs. (2) In the event appropriations from the General Revenue Fund are expended prior to the receipts of vendor drug rebates, HHSC shall reimburse the General Revenue Fund. HHSC shall reimburse the General Revenue Fund with vendor drug rebates on a monthly basis. (3) In the event HHSC expends vendor drug rebates in excess of amounts appropriated above in Strategies D.1.1, Women's Health Programs; D.1.7, Children with Special Needs; and D.1.9, Kidney Health Care, General Revenue Fund appropriations are reduced by a like amount. (d) Limited Use of Rebates. Rebates generated by a specific program shall only be used for that specific program. (e) Performance Reporting for the Prescription Drug Rebate Program. HHSC shall report the outstanding prescription drug rebate balances for Medicaid, CHIP, HTW, CSHCN, and KHC to HHSC shall report on an annual basis the following information to the Legislative Budget Board, the State Auditor's Office, the Comptroller of Public Accounts and the Office of the Governor no later than December 1, 2028.: the outstanding prescription drug rebate balances for the Medicaid, CHIP, HTW, CSHCN, and KHC. The report shall also include rebate principal and interest outstanding, age of receivables, and annual collection rates. The reports shall specify amounts billed, dollar value of pricing and utilization adjustments, and dollars collected. HHSC shall report these data on each fiscal year for which the Prescription Drug Rebate program has collected rebates and also on a cumulative basis for the last three five fiscal years.
Printed after the rider, with no marks. Reducing frequency of report to once per biennium would reduce associated staff workload. The proposed due date for the report in the even-numbered year would ensure that the information would be available prior to each legislative session.
This is usually the agency's explanation. The request does not mark it as language to add.